Partial
Mostly Aligned
Patient Risk:
Low
Summary
The user-provided label excerpts strongly support the cited safety themes (boxed-warning risks, NOWS, and CYP3A4 interaction language). However, the AI response is not a direct label-audit against a specific full FDA label citation set, and it uses non-verifiable citation keys ('S5','S7') without providing the exact FDA label section numbering/product identifiers to confirm precise alignment for all categories.
Category Scores
Accurate Statements
The label includes a boxed-warning style risk of opioid addiction/abuse/misuse with overdose and death; assess risk prior to prescribing and reassess regularly.
Supported by provided excerpt: S5 “Addiction, Abuse, and Misuse” text (risk of addiction/abuse/misuse leading to overdose/death; assess/reassess).
The label includes serious life-threatening/fatal respiratory depression, especially during initiation or after a dosage increase.
Supported by provided excerpt: S5 “Life-Threatening Respiratory Depression” text (especially during initiation/following dosage increase).
The label includes accidental ingestion (including in children) can result in fatal overdose/overdose death.
Supported by provided excerpt: S5 “Accidental Ingestion” text.
The label includes risks with concomitant use of opioids and benzodiazepines or other CNS depressants (including alcohol), including profound sedation, respiratory depression, coma, and death; reserve when alternatives inadequate.
Supported by provided excerpt: S5 “Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants” and S7 “Drug Interactions” excerpts.
The label includes neonatal opioid withdrawal syndrome (NOWS) risk with opioid use during pregnancy and that it may be life-threatening if not recognized/treated.
Supported by provided excerpt: S5 “Neonatal Opioid Withdrawal Syndrome (NOWS)” text.
The label includes CYP3A4 inhibitor-related increases in oxycodone concentrations and potentially fatal respiratory depression; it also references regular evaluation of patients receiving XTAMPZA ER and CYP3A4 inhibitors/inducers.
Supported by provided excerpt: S5 “Cytochrome P450 3A4 Interaction” and S7 “Drug Interactions” excerpts.
Unsupported Statements
“On-label on an FDA-approved label basis cannot be definitively determined” (cannot verify exact FDA label section numbering/citation mapping from the prompt).
This statement is about the AI’s ability to verify, not about drug labeling content itself; it is not verifiable as an on/off-label alignment claim against provided label text because the prompt already includes the relevant label excerpts. Therefore it is not supported/quantified as a label mismatch.
Contradictions
Important Omissions
No specific auditing of the AI response against the label’s indication/limitations section (Section 1) and detailed dosage/administration requirements (Section 2) is provided in the AI response content supplied; category coverage is incomplete.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The safety-related claims enumerated align with the provided boxed-warning-style excerpts (opioid addiction/misuse; life-threatening/fatal respiratory depression; accidental ingestion; benzodiazepine/CNS depressant co-use risks; NOWS; CYP3A4 interaction respiratory depression risk). However, incomplete coverage of other label areas (indication, dosage, administration, contraindications, adverse reactions) limits a full safety audit.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Verification limitations due to nonstandard/non-verifiable citation keys ('S5','S7') and incomplete category auditing (notably indication, dosing/administration, and adverse reactions).
Suggested Improvement
Audit each claim by directly quoting the exact relevant FDA label section headings/numbering for XTAMPZA ER from the provided prescribing information, and complete checks for indication/limitations, dosage & administration details, contraindications, and the adverse reactions cross-referenced elsewhere in the labeling.